Literature DB >> 23904234

What challenges remain in chronic myeloid leukemia research?

Angelo M Carella, Susan Branford, Michael Deininger, Francois X Mahon, Giuseppe Saglio, Anna Eiring, Jamshid Khorashad, Thomas O'Hare, John M Goldman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23904234      PMCID： PMC3729896          DOI： 10.3324/haematol.2013.090381

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  45 in total

1.  High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.

Authors:  Concetta Quintarelli; Gianpietro Dotti; Sayyeda T Hasan; Biagio De Angelis; Valentina Hoyos; Santa Errichiello; Martha Mims; Luigia Luciano; Jessica Shafer; Ann M Leen; Helen E Heslop; Cliona M Rooney; Fabrizio Pane; Malcolm K Brenner; Barbara Savoldo
Journal:  Blood       Date:  2011-01-28       Impact factor: 22.113

2.  Chronic myeloid leukemia: the basis of treatment for tomorrow.

Authors:  Angelo M Carella; John M Goldman; Giovanni Martinelli; Junia V Melo; Danilo Perrotti
Journal:  Haematologica       Date:  2011-12       Impact factor: 9.941

3.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

Authors:  Philippe Rousselot; Francoise Huguet; Delphine Rea; Laurence Legros; Jean Michel Cayuela; Odile Maarek; Odile Blanchet; Gerald Marit; Eliane Gluckman; Josy Reiffers; Martine Gardembas; François-Xavier Mahon
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

4.  Ponatinib for chronic myeloid leukemia.

Authors:  John M Goldman
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

5.  Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.

Authors:  Jorge Cortes; John M Goldman; Timothy Hughes
Journal:  J Natl Compr Canc Netw       Date:  2012-10-01       Impact factor: 11.908

6.  Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Authors:  Tao Dao; Su Yan; Nicholas Veomett; Dmitry Pankov; Liang Zhou; Tatyana Korontsvit; Andrew Scott; Joseph Whitten; Peter Maslak; Emily Casey; Taochao Tan; Hong Liu; Victoria Zakhaleva; Michael Curcio; Ekaterina Doubrovina; Richard J O'Reilly; Cheng Liu; David A Scheinberg
Journal:  Sci Transl Med       Date:  2013-03-13       Impact factor: 17.956

Review 7.  Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.

Authors:  Hagop M Kantarjian; Michele Baccarani; Elias Jabbour; Giuseppe Saglio; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2011-02-09       Impact factor: 12.531

8.  Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

Authors:  Wendy T Parker; Musei Ho; Hamish S Scott; Timothy P Hughes; Susan Branford
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

9.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

Authors:  Cristian Bellodi; Maria Rosa Lidonnici; Ashley Hamilton; G Vignir Helgason; Angela Rachele Soliera; Mattia Ronchetti; Sara Galavotti; Kenneth W Young; Tommaso Selmi; Rinat Yacobi; Richard A Van Etten; Nick Donato; Ann Hunter; David Dinsdale; Elena Tirrò; Paolo Vigneri; Pierluigi Nicotera; Martin J Dyer; Tessa Holyoake; Paolo Salomoni; Bruno Calabretta
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

10.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors:  Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
View more
  8 in total

Review 1.  Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights.

Authors:  Nicholas R Harrison; Fabrice J F Laroche; Alejandro Gutierrez; Hui Feng
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 2.  Present results and future perspectives in optimizing chronic myeloid leukemia therapy.

Authors:  Angelo M Carella; Giuseppe Saglio; Xavier F Mahon; Michael J Mauro
Journal:  Haematologica       Date:  2018-06       Impact factor: 9.941

3.  Serum Estrogen and its Soluble Receptor Levels in Egyptian Patients with Chronic Myeloid Leukemia: A Case-Control Study.

Authors:  Samir Ali Abd El-Kaream; Samia Abd El-Moneim Ebied; Nadia Aly Sadek; Khaled Abdel-Haleem Attia; Eman Attia Nadwan
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-23       Impact factor: 0.900

4.  Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report.

Authors:  Shiue-Wei Lai; Tzu-Chuan Huang; Jia-Hong Chen; Yi-Ying Wu; Ping-Ying Chang
Journal:  Oncol Lett       Date:  2015-02-03       Impact factor: 2.967

5.  Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.

Authors:  Raquel Vinhas; Alexandra R Fernandes; Pedro V Baptista
Journal:  Mol Ther Nucleic Acids       Date:  2017-05-08

6.  MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia.

Authors:  Bing Liu; Hongye Ma; Qianqian Liu; Yang Xiao; Shimeng Pan; Huimin Zhou; Li Jia
Journal:  J Exp Clin Cancer Res       Date:  2019-05-16

7.  Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.

Authors:  A G Smith; D Painter; D A Howell; P Evans; G Smith; R Patmore; A Jack; E Roman
Journal:  BMJ Open       Date:  2014-01-15       Impact factor: 2.692

8.  The IGF2/IGF1R/Nanog Signaling Pathway Regulates the Proliferation of Acute Myeloid Leukemia Stem Cells.

Authors:  Dan-Dan Xu; Ying Wang; Peng-Jun Zhou; Shu-Rong Qin; Rong Zhang; Yi Zhang; Xue Xue; Jianping Wang; Xia Wang; Hong-Ce Chen; Xiao Wang; Yu-Wei Pan; Li Zhang; Hai-Zhao Yan; Qiu-Ying Liu; Zhong Liu; Su-Hong Chen; Hong-Yuan Chen; Yi-Fei Wang
Journal:  Front Pharmacol       Date:  2018-06-29       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.